Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Efavirenz o nevirapina en el tratamiento de combinación de tres fármacos con dos inhibidores nucleósidos de la transcriptasa inversa para el tratamiento inicial de la infección por VIH en individuos que nunca recibieron tratamiento antirretroviral

Esta versión no es la más reciente

ver la versión actual 10 diciembre 2016

Información

DOI:
https://doi.org/10.1002/14651858.CD004246.pub3Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 08 diciembre 2010see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de VIH/SIDA

Copyright:
  1. Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Lawrence CE Mbuagbaw

    Correspondencia a: Centre for the Development of Best Practices in Health, Yaoundé, Cameroon

    [email protected]

  • James H Irlam

    Primary Health Care Directorate, University of Cape Town, Cape Town, South Africa

  • Alicen Spaulding

    Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, USA

  • George W Rutherford

    Global Health Sciences, University of California, San Francisco, San Francisco, USA

  • Nandi Siegfried

    Department of Public Health and Primary Health Care, University of Cape Town, Cape Town, South Africa

Contributions of authors

All authors contributed to the design and conduct of this study, as well as with manuscript drafting and submission.

Sources of support

Internal sources

  • South African Cochrane Centre, Medical Research Council, South Africa.

  • Cochrane HIV/AIDS Mentoring Programme, South Africa.

External sources

  • Centers for Disease Control and Prevention (CDC), USA.

    Cooperative Agreement #U2GPS001468 "Atlanta HQ UCSF Technical Assistance to Support the President's Emergency Plan for AIDS Relief" from the Centers for Disease Control and Prevention (CDC), with funds from National Center for HIV, Viral Hepatitis, STDs and TB Prevention (NCHSTP). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.

  • World Health Organization, Switzerland.

    World Health Organization #200106621, Systematic reviews and development of GRADE profiles, based on the new WHO GRC guidelines, for the "WHO Guidelines on antiretroviral therapy for HIV infection in adults and adolescents ‐ 2009 revision."

Declarations of interest

None known.

Acknowledgements

Dr Lawrence Mbuagbaw was awarded a Reviews for Africa Programme Fellowship (http://www.mrc.ac.za/cochrane/rap.htm), funded by a grant from the Nuffield Commonwealth Programme, through The Nuffield Foundation.

We acknowledge the assistance of the South African Cochrane Centre and Cochrane HIV/AIDS Review Group Mentoring Programme. James Irlam provided mentorship to Lawrence Mbuagbaw.

We gratefully acknowledge the contributions of Nancy Santesso and Holger Schunemann for their consultation and technical expertise with GRADEPro and Grade Tables presented in this review. We would also like to thank Tara Horvath and Joy Oliver for their assistance with searches. We would like to thank Gail Kennedy, Eliza Humphreys, Larry Chang and Jamal Harris for their collaboration and support.

We also acknowledge the collaboration of the trial authors who shared their data.

Version history

Published

Title

Stage

Authors

Version

2016 Dec 10

Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals

Review

Lawrence Mbuagbaw, Sara Mursleen, James H Irlam, Alicen B Spaulding, George W Rutherford, Nandi Siegfried

https://doi.org/10.1002/14651858.CD004246.pub4

2010 Dec 08

Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals

Review

Lawrence CE Mbuagbaw, James H Irlam, Alicen Spaulding, George W Rutherford, Nandi Siegfried

https://doi.org/10.1002/14651858.CD004246.pub3

2009 Apr 15

Efavirenz versus nevirapine as a non‐nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection

Protocol

Lawrence CE Mbuagbaw, James H Irlam

https://doi.org/10.1002/14651858.CD004246.pub2

2002 Oct 21

Efavirenz versus nevirapine as a non‐nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection

Protocol

Melissa Deanne Neuwelt

https://doi.org/10.1002/14651858.CD004246

Differences between protocol and review

Searches: AIDSearch was no longer available at the time of the searches.

National Library of Medicine Gateway was searched.

In the protocol we stated that we would include randomised controlled trials and observational cohorts. We did not include any observational cohorts in this review.

In the protocol, undetectable viral load was defined as less than 500copies/ml to include as many trials as possible and 50 copies/ml limit of detection for sub‐group analyses. Four of the trials included used the 50 copies/ml cut‐off and two used a 400 copies/ml cut‐off.

We did not abstract any time‐to‐event data.

Notes

None.

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.